NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) — Jonathan Jorgl, a shareholder of AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”), along with his nominees Robert L. Chioini and Michael Rice (collectively the The “AIM Stockholder Full Value Committee” or the “ASFV Committee”) announced today that on October 28, 2022, the Delaware Court of Chancery found that Mr. Jorgl failed to satisfy his burden of proving his claim for mandatory injunctive relief Questions of fact prevented Mr. Jorgl from issuing a final judgment, which is why Mr. Jorgl’s application for a temporary injunction was rejected. The ASFV Committee fundamentally disagrees with the verdict and the conclusions of the court on factual and legal issues. However, given the late date of the verdict and the forthcoming annual meeting on November 3, 2022, the ASFV Committee does not currently intend to go to court or to appeal.

Consequently, and as stated in the ASFV Committee Proxy Statement, we cannot nominate Mr. Chioini and Mr. Rice for election to the Board of Directors and proxies granted to us will not be put to a vote at the Annual Meeting. Any shareholder who has previously presented a gold proxy card to the ASFV Committee and wishes to be represented at the Annual Meeting should consult the Company’s proxy documentation for information. how to vote either in person or by proxy. Although shareholders will not be able to vote for Mr. Chioini and Mr. Rice at the annual meeting or through the Company’s voting records, shareholders will retain the ability to “withhold” their votes for the acting directors and vote against the Company’s voting vote – payment proposal.

The ASFV Committee unequivocally reiterates our position that Mr. Jorgl’s nominations were not made pursuant to any secret agreement or understanding and that his disclosure was consistent with the Company’s Articles of Association. Based on the ASFV committee’s proxy statement, which we believe…